



Belgian Cancer Registry

# CANCER FACT SHEET 2023

## PANCREATIC CANCER

### ICD-10 C25



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

**ADC:** Adenocarcinoma.

**NENs:** Neuroendocrine neoplasms.



1. CANCER INCIDENCE .....	5
1.1. Pancreatic cancer incidence: by region .....	5
1.1.1. Pancreatic cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023.....	5
1.2. Pancreatic cancer incidence: by tumour stage .....	7
1.2.1. Pancreatic cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023 .....	7
1.2.2. Pancreatic cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	7
1.2.3. Pancreatic cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	8
1.3. Pancreatic cancer incidence: by tumour type .....	9
1.3.1. Pancreatic cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023 .....	9
1.4. Pancreatic cancer incidence: by tumour type and tumour stage .....	10
1.4.1. Pancreatic cancer incidence by tumour type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	10
2. CANCER INCIDENCE TRENDS .....	11
2.1. Pancreatic cancer incidence trends: by region.....	11
2.1.1. Pancreatic cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	11
2.1.2. Pancreatic cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	13
2.2. Pancreatic cancer incidence trends: by tumour stage .....	14
2.2.1. Pancreatic cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards...	14
2.3. Pancreatic cancer incidence trends: by age group.....	16
2.3.1. Pancreatic cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	16
2.3.2. Pancreatic cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	17
3. CANCER PREVALENCE .....	18
3.1. Pancreatic cancer prevalence: by region.....	18
3.1.1. Pancreatic cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023.....	18
4. CANCER SURVIVAL.....	19
4.1. Pancreatic cancer survival: by region .....	19
4.1.1. Pancreatic cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023.....	19
4.2. Pancreatic cancer survival: by tumour stage .....	21

4.2.1. Pancreatic cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023 .....	21
4.2.2. Pancreatic cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2014-2023 .....	22
4.2.3. Pancreatic cancer survival by stage and sex: number at risk and net survival probabilities, 2014-2023.....	23
4.3. Pancreatic cancer survival: by tumour type and tumour stage .....	24
4.3.1. Pancreatic cancer survival by type, stage and sex: number at risk and net survival probabilities, 2014-2023 .....	24
5. CANCER SURVIVAL TRENDS.....	27
5.1. Pancreatic cancer survival trends: by tumour stage.....	27
5.1.1. Pancreatic cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023 .....	27
5.2. Pancreatic cancer survival trends: by tumour type and tumour stage.....	29
5.2.1. Pancreatic cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2023 .....	29
6. CANCER MORTALITY .....	33
6.1. Pancreatic cancer mortality: by region.....	33
6.1.1. Pancreatic cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....	33
7. CANCER MORTALITY TRENDS.....	35
7.1. Pancreatic cancer mortality trends: by region .....	35
7.1.1. Pancreatic cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	35
7.1.2. Pancreatic cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	36



# 1. CANCER INCIDENCE



## 1.1. Pancreatic cancer incidence: by region

1.1.1. Pancreatic cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	0	0	3	2	7	12	24	56	99	149	172	207	202	131	68	16	1	1,149	21.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.5]	[1.9]	[3.1]	[6.4]	[14.2]	[24.6]	[39.8]	[54.1]	[77.7]	[99.4]	[104.9]	[85.3]	[51.1]	[16.5]	[19.9]	(19.8; 22.3)
Brussels	0	0	0	0	0	0	1	0	2	5	9	12	11	9	18	10	6	3	1	0	87	21.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[4.3]	[11.4]	[22.0]	[33.9]	[38.1]	[42.1]	[107.0]	[79.2]	[74.6]	[60.0]	[43.4]	[0.0]	[14.3]	(16.6; 25.8)
Flanders	0	0	0	0	0	2	0	5	9	13	33	57	84	109	112	127	84	52	8	1	696	20.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.0]	[2.4]	[4.1]	[6.2]	[14.4]	[23.5]	[36.7]	[55.6]	[68.2]	[97.4]	[101.9]	[96.7]	[38.5]	[25.2]	[20.8]	(18.9; 21.9)
Wallonia	0	0	0	0	0	1	1	2	1	6	14	30	54	54	77	65	41	13	7	0	366	22.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.8]	[1.7]	[0.9]	[5.1]	[11.2]	[24.0]	[46.2]	[53.6]	[90.2]	[107.8]	[119.2]	[62.1]	[85.1]	[0.0]	[20.3]	(19.8; 24.4)
Females																						
Belgium	0	0	0	0	1	2	5	10	13	23	42	83	125	145	191	202	138	104	34	4	1,122	17.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.6]	[1.3]	[2.6]	[3.4]	[6.3]	[10.8]	[20.9]	[32.7]	[42.8]	[64.3]	[82.2]	[79.2]	[77.7]	[48.0]	[19.2]	[18.9]	(16.5; 18.5)
Brussels	0	0	0	0	0	1	3	2	2	5	5	4	13	9	16	18	11	9	2	0	100	19.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[5.5]	[4.2]	[4.4]	[12.2]	[13.1]	[11.7]	[43.0]	[36.0]	[74.6]	[100.0]	[85.6]	[91.8]	[35.3]	[0.0]	[15.8]	(15.8; 23.6)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	2	6	8	9	18	41	71	88	113	121	99	66	18	2	662	17.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.8]	[3.6]	[4.3]	[8.0]	[17.3]	[31.1]	[43.5]	[64.4]	[80.5]	[90.5]	[77.3]	[40.9]	[16.3]	[19.3]	(15.7; 18.3)
Wallonia	0	0	0	0	1	1	0	2	3	9	19	38	41	48	62	63	28	29	14	2	360	17.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[1.7]	[2.5]	[7.6]	[15.2]	[30.0]	[33.3]	[43.1]	[62.0]	[81.4]	[53.9]	[75.0]	[66.1]	[30.8]	[19.1]	(15.9; 19.6)

## 1.2. Pancreatic cancer incidence: by tumour stage

1.2.1. Pancreatic cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	55 [1.6]	126 [13.1]	102 [22.9]	283 [4.9]	5.2 (4.6; 5.8)	58 [1.7]	102 [10.0]	105 [16.3]	265 [4.5]	4.2 (3.7; 4.7)
II	37 [1.1]	65 [6.8]	48 [10.8]	150 [2.6]	2.7 (2.3; 3.2)	20 [0.6]	78 [7.7]	75 [11.6]	173 [2.9]	2.7 (2.3; 3.1)
III	23 [0.7]	60 [6.3]	47 [10.6]	130 [2.3]	2.4 (2.0; 2.8)	19 [0.6]	59 [5.8]	41 [6.4]	119 [2.0]	1.9 (1.5; 2.2)
IV	83 [2.5]	259 [27.0]	200 [44.9]	542 [9.4]	9.9 (9.1; 10.8)	72 [2.2]	203 [20.0]	231 [35.8]	506 [8.5]	7.9 (7.2; 8.6)
X/NA	5 [0.1]	18 [1.9]	21 [4.7]	44 [0.8]	0.8 (0.6; 1.1)	10 [0.3]	19 [1.9]	30 [4.6]	59 [1.0]	0.9 (0.6; 1.1)

1.2.2. Pancreatic cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	26 [0.8]	45 [4.7]	31 [7.0]	102 [1.8]	1.8 (1.5; 2.2)	26 [0.8]	46 [4.5]	23 [3.6]	95 [1.6]	1.6 (1.2; 1.9)
II	15 [0.4]	50 [5.2]	31 [7.0]	96 [1.7]	1.7 (1.4; 2.1)	27 [0.8]	46 [4.5]	28 [4.3]	101 [1.7]	1.6 (1.3; 2.0)
III	27 [0.8]	41 [4.3]	20 [4.5]	88 [1.5]	1.6 (1.2; 1.9)	7 [0.2]	34 [3.3]	16 [2.5]	57 [1.0]	0.9 (0.7; 1.2)
IV	23 [0.7]	67 [7.0]	45 [10.1]	135 [2.3]	2.5 (2.0; 2.9)	23 [0.7]	70 [6.9]	51 [7.9]	144 [2.4]	2.3 (1.9; 2.7)
X/NA	112 [3.3]	325 [33.9]	291 [65.4]	728 [12.6]	13.4 (12.4; 14.4)	96 [2.9]	265 [26.0]	364 [56.4]	725 [12.2]	11.1 (10.3; 11.9)

1.2.3. Pancreatic cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	48 [1.4]	93 [9.7]	87 [19.5]	228 [4.0]	4.2 (3.6; 4.7)	42 [1.3]	74 [7.3]	83 [12.9]	199 [3.4]	3.1 (2.7; 3.5)
II	26 [0.8]	77 [8.0]	54 [12.1]	157 [2.7]	2.9 (2.4; 3.3)	35 [1.1]	86 [8.5]	82 [12.7]	203 [3.4]	3.2 (2.8; 3.6)
III	42 [1.2]	83 [8.7]	59 [13.2]	184 [3.2]	3.3 (2.9; 3.8)	24 [0.7]	80 [7.9]	54 [8.4]	158 [2.7]	2.5 (2.1; 2.9)
IV	84 [2.5]	264 [27.5]	205 [46.0]	553 [9.6]	10.1 (9.3; 11.0)	74 [2.2]	212 [20.8]	236 [36.6]	522 [8.8]	8.1 (7.4; 8.9)
X/NA	3 [0.1]	11 [1.1]	13 [2.9]	27 [0.5]	0.5 (0.3; 0.7)	4 [0.1]	9 [0.9]	27 [4.2]	40 [0.7]	0.6 (0.4; 0.7)



### 1.3. Pancreatic cancer incidence: by tumour type

1.3.1. *Pancreatic cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
<b>ADC</b>	144 [4.3]	426 [44.4]	298 [66.9]	868 [15.1]	15.8 (14.8; 16.9)	128 [3.8]	376 [37.0]	346 [53.6]	850 [14.3]	13.4 (12.5; 14.3)
<b>NENs</b>	47 [1.4]	64 [6.7]	34 [7.6]	145 [2.5]	2.6 (2.2; 3.0)	44 [1.3]	46 [4.5]	29 [4.5]	119 [2.0]	1.9 (1.6; 2.3)
<b>Other and unspecified</b>	12 [0.4]	38 [4.0]	86 [19.3]	136 [2.4]	2.6 (2.2; 3.0)	7 [0.2]	39 [3.8]	107 [16.6]	153 [2.6]	2.1 (1.8; 2.5)

## 1.4. Pancreatic cancer incidence: by tumour type and tumour stage

1.4.1. Pancreatic cancer incidence by tumour type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
ADC	I	22 [0.7]	52 [5.4]	54 [12.1]	128 [2.2]	2.4 (1.9; 2.8)	17 [0.5]	49 [4.8]	52 [8.1]	118 [2.0]	1.8 (1.5; 2.2)
	II	22 [0.7]	63 [6.6]	44 [9.9]	129 [2.2]	2.4 (2.0; 2.8)	28 [0.8]	73 [7.2]	66 [10.2]	167 [2.8]	2.7 (2.3; 3.1)
	III	34 [1.0]	72 [7.5]	44 [9.9]	150 [2.6]	2.7 (2.3; 3.2)	22 [0.7]	68 [6.7]	43 [6.7]	133 [2.2]	2.1 (1.8; 2.5)
	IV	64 [1.9]	231 [24.1]	148 [33.2]	443 [7.7]	8.0 (7.3; 8.8)	58 [1.7]	181 [17.8]	169 [26.2]	408 [6.9]	6.5 (5.8; 7.1)
	X/NA	2 [0.1]	8 [0.8]	8 [1.8]	18 [0.3]	0.3 (0.2; 0.5)	3 [0.1]	5 [0.5]	16 [2.5]	24 [0.4]	0.3 (0.2; 0.5)
NENs	I	24 [0.7]	34 [3.5]	15 [3.4]	73 [1.3]	1.3 (1.0; 1.6)	22 [0.7]	20 [2.0]	14 [2.2]	56 [0.9]	0.9 (0.7; 1.2)
	II	2 [0.1]	10 [1.0]	8 [1.8]	20 [0.3]	0.4 (0.2; 0.5)	7 [0.2]	7 [0.7]	5 [0.8]	19 [0.3]	0.3 (0.2; 0.4)
	III	7 [0.2]	7 [0.7]	4 [0.9]	18 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	2 [0.2]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
	IV	13 [0.4]	12 [1.3]	7 [1.6]	32 [0.6]	0.6 (0.4; 0.8)	12 [0.4]	14 [1.4]	7 [1.1]	33 [0.6]	0.5 (0.4; 0.7)
	X/NA	1 [0.0]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	3 [0.3]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.1)
Other and unspecified	I	2 [0.1]	7 [0.7]	18 [4.0]	27 [0.5]	0.5 (0.3; 0.7)	3 [0.1]	5 [0.5]	17 [2.6]	25 [0.4]	0.4 (0.2; 0.5)
	II	2 [0.1]	4 [0.4]	2 [0.4]	8 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	6 [0.6]	11 [1.7]	17 [0.3]	0.2 (0.1; 0.3)
	III	1 [0.0]	4 [0.4]	11 [2.5]	16 [0.3]	0.3 (0.2; 0.5)	0 [0.0]	10 [1.0]	9 [1.4]	19 [0.3]	0.3 (0.1; 0.4)
	IV	7 [0.2]	21 [2.2]	50 [11.2]	78 [1.4]	1.5 (1.2; 1.8)	4 [0.1]	17 [1.7]	60 [9.3]	81 [1.4]	1.1 (0.9; 1.4)
	X/NA	0 [0.0]	2 [0.2]	5 [1.1]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	1 [0.1]	10 [1.5]	11 [0.2]	0.1 (0.1; 0.2)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Pancreatic cancer incidence trends: by region

2.1.1. Pancreatic cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium <b>N</b>	572	545	615	647	597	713	788	782	814	860	873	890	900	984	1,054	1,053	1,045	1,181	1,135	1,149		
<b>CR</b>	11.2	10.7	12.0	12.5	11.4	13.5	14.8	14.6	15.0	15.8	15.9	16.2	16.3	17.7	18.8	18.7	18.5	20.8	19.9	19.9		
<b>ESR2013</b>	14.1	13.0	14.8	14.9	13.8	16.2	17.8	17.3	17.7	18.5	18.4	18.4	18.6	19.8	21.1	20.4	20.2	22.4	21.3	21.0	2.7 (2.3; 3.0)	2004-2023
																					3.8 (2.7; 4.8)	2004-2012
																					1.9 (1.1; 2.6)	2013-2023
Brussels <b>N</b>	50	39	39	62	66	63	69	62	72	63	68	84	67	83	75	77	69	86	75	87		
<b>CR</b>	10.4	8.1	8.0	12.5	13.1	12.2	13.1	11.4	13.0	11.2	12.0	14.7	11.6	14.3	12.8	13.0	11.5	14.4	12.5	14.3		
<b>ESR2013</b>	14.8	11.8	11.2	18.7	19.7	18.9	19.7	17.4	20.9	17.9	18.9	22.7	18.2	22.5	20.2	20.0	17.8	22.7	19.9	21.2	2.3 (1.2; 3.4)	2004-2023
																					5.5 (2.4; 8.6)	2004-2012
																					0.1 (-1.9; 2.1)	2013-2023
Flanders <b>N</b>	335	325	360	354	356	397	443	430	484	497	489	513	545	568	663	622	619	683	686	696		
<b>CR</b>	11.3	10.9	12.0	11.7	11.7	13.0	14.4	13.8	15.4	15.8	15.4	16.1	17.0	17.6	20.5	19.1	18.9	20.7	20.7	20.8		
<b>ESR2013</b>	13.7	12.9	14.2	13.2	13.5	14.7	16.3	15.3	17.0	17.3	16.6	17.1	18.1	18.4	21.5	19.5	19.3	20.8	20.6	20.4	2.7 (2.3; 3.1)	2004-2023
Wallonia <b>N</b>	187	181	216	231	175	253	276	290	258	300	316	293	288	333	316	354	357	412	374	366		
<b>CR</b>	11.4	11.0	13.0	13.9	10.4	15.0	16.2	16.9	15.0	17.3	18.1	16.7	16.4	18.9	17.9	19.9	20.0	23.1	20.9	20.3		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
ESR2013	14.7	13.7	16.9	17.4	13.2	18.6	20.3	21.2	18.4	21.1	21.8	20.0	19.4	22.2	20.5	22.4	22.6	25.5	23.2	22.1	2.5 (1.7; 3.4)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Pancreatic cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium <b>N</b>	499	531	575	546	582	663	737	758	750	814	848	893	903	900	990	1,001	1,026	1,114	1,050	1,122		
<b>CR</b>	9.4	10.0	10.7	10.1	10.7	12.1	13.3	13.6	13.3	14.4	14.9	15.7	15.8	15.6	17.1	17.2	17.6	19.1	17.9	18.9		
<b>ESR2013</b>	9.6	10.1	10.8	10.2	10.6	12.0	13.1	13.4	13.1	14.0	14.6	15.1	15.1	15.0	16.2	16.3	16.4	17.7	16.5	17.5	3.2 (2.9; 3.6)	2004-2023
																					4.4 (3.7; 5.1)	2004-2014
																					2.0 (1.3; 2.7)	2015-2023
Brussels <b>N</b>	43	35	68	39	59	63	69	70	67	69	79	74	82	86	72	74	71	84	84	100		
<b>CR</b>	8.3	6.7	12.9	7.3	10.9	11.4	12.3	12.1	11.4	11.6	13.2	12.3	13.5	14.1	11.8	12.0	11.4	13.5	13.5	15.8		
<b>ESR2013</b>	9.1	7.7	15.0	8.2	12.5	13.6	14.9	13.8	13.8	13.5	16.5	15.0	16.4	17.6	14.4	14.6	14.4	16.8	17.1	19.7	3.2 (1.8; 4.6)	2004-2023
Flanders <b>N</b>	283	311	301	319	316	381	416	416	446	463	499	492	517	508	616	566	624	672	625	662		
<b>CR</b>	9.3	10.2	9.8	10.3	10.1	12.1	13.1	13.0	13.9	14.3	15.4	15.1	15.8	15.4	18.6	17.0	18.6	20.0	18.5	19.3		
<b>ESR2013</b>	9.3	10.1	9.7	10.1	9.8	11.6	12.5	12.4	13.1	13.4	14.4	14.0	14.5	13.9	16.9	15.3	16.5	17.6	16.3	17.0	3.4 (3.0; 3.9)	2004-2023
																					4.4 (3.5; 5.3)	2004-2014
																					2.4 (1.4; 3.4)	2015-2023
Wallonia <b>N</b>	173	185	206	188	207	219	252	272	237	282	270	327	304	306	302	361	331	358	341	360		
<b>CR</b>	9.9	10.6	11.7	10.6	11.6	12.3	14.0	15.0	13.0	15.4	14.7	17.8	16.5	16.5	16.3	19.4	17.8	19.2	18.2	19.1		
<b>ESR2013</b>	10.2	10.9	11.8	10.8	11.7	12.6	14.0	15.2	13.0	15.1	14.3	17.2	15.9	16.2	15.4	18.6	16.7	18.0	16.8	17.7	2.9 (2.4; 3.5)	2004-2023
																					4.2 (3.1; 5.3)	2004-2014
																					1.6 (0.3; 2.8)	2015-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Pancreatic cancer incidence trends: by tumour stage

2.2.1. Pancreatic cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		Males							Females									
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period			
I	N	171	137	179	186	228	8.9 (7.0; 10.9)	2004-2023	149	156	216	190	199	10.0 (8.8; 11.3)	2004-2023			
	CR	3.0	2.4	3.2	3.3	4.0			2.6	2.7	3.7	3.2	3.4					
	ESR2013	3.3	2.6	3.4	3.5	4.2			2.4	2.5	3.4	2.9	3.1					
II	N	174	168	176	185	157	1.1 (0.2; 2.0)	2004-2023	160	150	169	144	203	1.5 (0.2; 2.8)	2004-2023			
	CR	3.1	3.0	3.1	3.2	2.7			2.8	2.6	2.9	2.5	3.4					
	ESR2013	3.4	3.3	3.3	3.5	2.9			2.6	2.4	2.7	2.3	3.2					
																	7.3 (3.2; 11.6)	2004-2011
																	1.5 (-4.3; 7.7)	2012-2015
															-3.4 (-6.5; -0.1)	2016-2023		
III	N	145	160	176	174	184	8.5 (6.7; 10.3)	2004-2023	119	152	167	162	158	7.2 (5.5; 8.9)	2004-2023			
	CR	2.6	2.8	3.1	3.0	3.2			2.1	2.6	2.9	2.8	2.7					
	ESR2013	2.8	3.1	3.3	3.2	3.3			2.0	2.5	2.7	2.6	2.5					
																	3.5 (0.9; 6.3)	2004-2016
																	13.7 (8.4; 19.3)	2017-2023
IV	N	475	519	600	561	553	4.3 (3.7; 5.0)	2004-2023	489	514	525	507	522	5.5 (5.0; 6.0)	2004-2023			
	CR	8.4	9.2	10.6	9.8	9.6			8.4	8.8	9.0	8.6	8.8					
	ESR2013	9.2	10.0	11.3	10.5	10.1			8.0	8.2	8.4	7.9	8.1					
																	6.9 (6.0; 7.8)	2004-2016
																	3.1 (1.5; 4.8)	2017-2023
X/NA	N	88	61	50	29	27			84	54	37	47	40					

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
<b>CR</b>	1.6	1.1	0.9	0.5	0.5			1.4	0.9	0.6	0.8	0.7		
<b>ESR2013</b>	1.7	1.2	1.0	0.6	0.5	-11.0 (-11.8; -10.2)	2004-2023	1.3	0.8	0.5	0.7	0.6	-9.1 (-10.3; -7.9)	2004-2023
						-3.1 (-5.0; -1.3)	2004-2013						-1.3 (-3.7; 1.2)	2004-2015
						-5.9 (-9.6; -2.0)	2014-2017						-18.8 (-21.7; -15.9)	2016-2023
						-24.5 (-26.8; -22.0)	2018-2023							

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.3. Pancreatic cancer incidence trends: by age group

2.3.1. Pancreatic cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
<b>15-59 N</b>	133	140	145	169	137	161	157	176	166	166	195	180	162	183	185	202	186	219	187	203	1.3 (0.8; 1.9)	2004-2023
<b>CR</b>	4.2	4.4	4.5	5.2	4.2	4.9	4.8	5.3	5.0	5.0	5.9	5.4	4.9	5.5	5.5	6.1	5.6	6.6	5.6	6.0		
<b>ESR2013</b>	4.4	4.6	4.7	5.4	4.3	5.1	4.9	5.4	5.0	5.0	5.8	5.4	4.8	5.4	5.4	5.9	5.4	6.4	5.4	5.9		
<b>60-74 N</b>	285	250	267	287	277	331	350	351	392	413	378	417	396	462	508	522	475	563	524	528	2.5 (1.9; 3.0)	2004-2023
<b>CR</b>	41.9	36.5	38.9	41.0	38.9	45.5	47.2	46.4	51.0	52.7	47.4	51.3	47.6	53.9	57.8	58.1	51.8	60.2	55.4	55.0		
<b>ESR2013</b>	41.6	36.3	38.9	41.4	39.3	46.7	48.5	48.2	51.9	54.6	49.3	52.6	49.1	55.1	59.0	59.2	52.7	61.1	56.3	56.0		
<b>75+ N</b>	154	155	203	191	183	221	281	255	256	281	300	293	342	339	361	328	383	399	424	418	3.5 (2.9; 4.2)	2004-2023
<b>CR</b>	52.5	51.2	64.6	58.6	54.3	64.0	79.4	70.6	69.4	74.7	78.2	74.8	86.6	85.9	90.9	81.2	92.6	95.9	98.3	93.9		
<b>ESR2013</b>	51.1	48.4	62.6	54.8	53.4	61.4	76.7	68.3	69.0	72.3	75.7	73.2	85.0	84.3	90.6	79.8	92.2	94.7	98.3	92.4		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



2.3.2. Pancreatic cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
<b>15-59 N</b>	85	102	99	97	107	117	129	142	136	154	134	158	179	149	173	158	144	172	159	179		
<b>CR</b>	2.7	3.2	3.1	3.0	3.3	3.6	4.0	4.4	4.2	4.7	4.1	4.8	5.4	4.5	5.3	4.8	4.4	5.2	4.8	5.4		
<b>ESR2013</b>	2.8	3.4	3.2	3.1	3.4	3.7	4.0	4.4	4.2	4.7	4.0	4.7	5.3	4.4	5.2	4.7	4.2	5.1	4.7	5.3	3.0 (2.3; 3.6)	2004-2023
																					5.4 (3.7; 7.2)	2004-2012
																					1.2 (0.1; 2.4)	2013-2023
<b>60-74 N</b>	207	227	233	231	221	268	297	274	279	297	346	332	349	359	387	417	416	460	414	461		
<b>CR</b>	26.7	29.3	30.2	29.6	28.0	33.5	36.7	33.3	33.4	35.1	40.3	38.1	39.1	39.1	41.2	43.5	42.6	46.3	41.2	45.3		
<b>ESR2013</b>	26.1	28.7	29.9	29.4	28.2	33.9	36.9	34.0	34.0	35.8	41.2	39.1	39.5	39.9	41.6	43.8	42.9	46.4	41.5	45.7	2.8 (2.3; 3.3)	2004-2023
<b>75+ N</b>	206	202	243	218	254	277	311	342	335	363	368	401	375	392	430	425	466	481	474	482		
<b>CR</b>	39.6	38.0	44.6	39.1	44.6	47.9	53.0	57.6	55.8	60.1	60.3	65.0	60.8	64.0	70.4	69.2	75.1	77.7	74.8	74.7		
<b>ESR2013</b>	39.7	38.2	44.3	38.8	44.2	46.9	52.0	58.2	56.2	59.0	60.4	65.1	60.8	64.5	70.7	70.2	75.8	78.2	76.0	76.2	4.0 (3.6; 4.5)	2004-2023
																					5.3 (4.2; 6.3)	2004-2013
																					2.9 (2.0; 3.9)	2014-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

### 3. CANCER PREVALENCE



#### 3.1. Pancreatic cancer prevalence: by region

3.1.1. *Pancreatic cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023*

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	742	1,765	2,163	2,397	2,489	709	1,605	2,043	2,286	2,376
	CR	12.8	30.4	37.3	41.3	42.9	11.9	26.9	34.2	38.3	39.8
	ESR2013	13.2	31.4	38.6	42.8	44.5	11.1	25.4	32.3	36.1	37.5
Brussels	N	61	120	140	152	157	64	135	170	184	192
	CR	10.0	19.6	22.9	24.8	25.6	10.0	21.2	26.7	28.9	30.1
	ESR2013	13.8	28.3	33.4	36.6	37.7	12.2	25.8	32.4	35.2	36.9
Flanders	N	453	1,109	1,376	1,512	1,571	428	980	1,246	1,392	1,446
	CR	13.4	32.8	40.7	44.8	46.5	12.4	28.5	36.2	40.4	42.0
	ESR2013	13.0	32.0	39.7	43.7	45.4	11.1	25.6	32.6	36.4	37.8
Wallonia	N	228	536	647	733	761	217	490	627	710	738
	CR	12.6	29.7	35.8	40.6	42.1	11.5	26.0	33.3	37.7	39.2
	ESR2013	13.2	31.0	37.6	42.6	44.4	10.7	24.5	31.3	35.5	36.9

## 4. CANCER SURVIVAL



### 4.1. Pancreatic cancer survival: by region

4.1.1. Pancreatic cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	20,021	43.0% (42.3%; 43.7%)	19.5% (19.0%; 20.2%)	14.7% (14.1%; 15.4%)	11.9% (11.1%; 12.9%)
Males						
Belgium	All ages	10,214	43.4% (42.4%; 44.4%)	20.1% (19.2%; 20.9%)	15.2% (14.3%; 16.1%)	12.1% (10.8%; 13.5%)
	15-59	1,895	57.8% (55.6%; 60.0%)	30.1% (28.0%; 32.3%)	24.9% (22.9%; 27.2%)	20.3% (17.9%; 23.1%)
	60-74	4,750	48.1% (46.6%; 49.5%)	21.9% (20.7%; 23.2%)	16.4% (15.2%; 17.7%)	13.2% (11.5%; 15.1%)
	75+	3,569	29.7% (28.1%; 31.3%)	12.3% (11.0%; 13.6%)	8.4% (7.1%; 9.9%)	6.3% (4.2%; 9.4%)
Brussels	All ages	761	42.0% (38.5%; 45.7%)	15.5% (12.9%; 18.6%)	10.2% (7.8%; 13.3%)	8.5% (5.9%; 12.2%)
	15-59	182	51.1% (44.3%; 59.0%)	18.0% (12.8%; 25.2%)	12.9% (8.3%; 20.2%)	11.5% (6.9%; 19.2%)
	60-74	354	45.7% (40.7%; 51.3%)	19.9% (15.9%; 24.9%)	13.1% (9.5%; 18.1%)	11.5% (7.5%; 17.5%)
	75+	225	28.8% (23.2%; 35.7%)	6.7% (3.8%; 11.8%)	4.7% (2.1%; 10.3%)	FU<10y
Flanders	All ages	6,061	44.8% (43.5%; 46.1%)	21.8% (20.7%; 23.0%)	16.8% (15.7%; 18.1%)	13.7% (12.0%; 15.6%)
	15-59	1,049	60.0% (57.1%; 63.1%)	34.2% (31.3%; 37.3%)	28.4% (25.5%; 31.5%)	22.9% (19.4%; 27.1%)
	60-74	2,746	50.4% (48.5%; 52.3%)	23.6% (21.9%; 25.4%)	18.3% (16.6%; 20.1%)	14.3% (12.0%; 17.0%)
	75+	2,266	31.1% (29.1%; 33.2%)	13.9% (12.3%; 15.8%)	9.8% (8.1%; 11.9%)	8.4% (5.6%; 12.7%)
Wallonia	All ages	3,392	41.3% (39.6%; 43.0%)	17.9% (16.6%; 19.4%)	13.2% (11.9%; 14.7%)	9.8% (7.9%; 12.3%)

Net Survival Probability, 2014-2023							
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	<b>15-59</b>	664	56.0% (52.4%; 59.9%)	26.9% (23.6%; 30.6%)	22.6% (19.4%; 26.3%)	18.4% (15.1%; 22.5%)	
	<b>60-74</b>	1,650	44.8% (42.4%; 47.3%)	19.6% (17.7%; 21.8%)	13.9% (12.0%; 16.0%)	11.6% (9.1%; 14.7%)	
	<b>75+</b>	1,078	26.9% (24.2%; 29.8%)	10.0% (8.1%; 12.3%)	6.4% (4.6%; 8.9%)	FU<10y	
Females							
<b>Belgium</b>	<b>All ages</b>	9,807	42.5% (41.5%; 43.5%)	19.0% (18.2%; 19.9%)	14.3% (13.5%; 15.2%)	11.8% (10.5%; 13.1%)	
	<b>15-59</b>	1,591	67.4% (65.1%; 69.7%)	37.6% (35.2%; 40.1%)	31.4% (29.0%; 34.0%)	27.2% (24.4%; 30.4%)	
	<b>60-74</b>	3,927	48.9% (47.3%; 50.5%)	20.9% (19.6%; 22.3%)	14.8% (13.6%; 16.2%)	11.4% (9.9%; 13.1%)	
	<b>75+</b>	4,289	27.3% (26.0%; 28.8%)	10.4% (9.4%; 11.5%)	7.4% (6.3%; 8.6%)	6.2% (4.1%; 9.3%)	
Brussels	<b>All ages</b>	801	41.3% (37.9%; 44.9%)	18.5% (15.8%; 21.6%)	15.3% (12.7%; 18.4%)	11.9% (8.8%; 16.0%)	
	<b>15-59</b>	167	69.1% (62.4%; 76.6%)	41.1% (34.1%; 49.6%)	34.7% (27.6%; 43.6%)	33.4% (26.0%; 42.8%)	
	<b>60-74</b>	295	47.6% (42.2%; 53.8%)	21.3% (16.8%; 26.9%)	17.4% (13.1%; 23.1%)	14.4% (9.8%; 21.1%)	
	<b>75+</b>	339	22.2% (18.1%; 27.3%)	4.9% (2.9%; 8.4%)	3.7% (1.9%; 7.4%)	FU<10y	
Flanders	<b>All ages</b>	5,758	44.0% (42.7%; 45.3%)	20.3% (19.2%; 21.4%)	15.2% (14.1%; 16.4%)	12.8% (11.1%; 14.7%)	
	<b>15-59</b>	855	69.1% (66.1%; 72.3%)	38.5% (35.3%; 42.0%)	32.2% (29.0%; 35.7%)	28.2% (24.6%; 32.3%)	
	<b>60-74</b>	2,278	50.7% (48.7%; 52.8%)	22.7% (20.9%; 24.6%)	15.9% (14.2%; 17.7%)	11.3% (9.3%; 13.8%)	
	<b>75+</b>	2,625	30.0% (28.2%; 31.8%)	12.2% (10.8%; 13.7%)	8.9% (7.4%; 10.6%)	9.2% (6.0%; 14.1%)	
Wallonia	<b>All ages</b>	3,248	40.1% (38.4%; 41.8%)	16.9% (15.6%; 18.4%)	12.5% (11.3%; 13.9%)	9.9% (8.0%; 12.3%)	
	<b>15-59</b>	569	64.2% (60.4%; 68.3%)	35.1% (31.2%; 39.4%)	29.2% (25.4%; 33.6%)	24.0% (19.1%; 30.2%)	
	<b>60-74</b>	1,354	46.1% (43.5%; 48.9%)	17.8% (15.7%; 20.1%)	12.5% (10.6%; 14.7%)	10.6% (8.6%; 13.1%)	
	<b>75+</b>	1,325	23.5% (21.2%; 26.0%)	8.2% (6.7%; 10.1%)	5.4% (3.9%; 7.3%)	3.5% (1.6%; 7.7%)	

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

## 4.2. Pancreatic cancer survival: by tumour stage

### 4.2.1. Pancreatic cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	20,021	43.0% (42.3%; 43.7%)	26.1% (25.5%; 26.7%)	19.5% (19.0%; 20.2%)	16.5% (16.0%; 17.1%)	14.7% (14.1%; 15.4%)	11.9% (11.1%; 12.9%)
<b>Males</b>							
<b>All</b>	10,214	43.4% (42.4%; 44.4%)	26.4% (25.6%; 27.4%)	20.1% (19.2%; 20.9%)	17.1% (16.2%; 17.9%)	15.2% (14.3%; 16.1%)	12.1% (10.8%; 13.5%)
<b>I</b>	1,627	74.6% (72.3%; 76.9%)	56.8% (54.2%; 59.5%)	48.8% (46.1%; 51.8%)	43.1% (40.1%; 46.3%)	40.1% (36.9%; 43.5%)	37.5% (31.8%; 44.3%)
<b>II</b>	1,372	61.3% (58.6%; 64.0%)	40.1% (37.4%; 42.9%)	30.0% (27.4%; 32.8%)	25.5% (22.9%; 28.4%)	21.1% (18.5%; 24.1%)	17.3% (13.6%; 21.9%)
<b>III</b>	918	50.7% (47.5%; 54.2%)	24.2% (21.4%; 27.3%)	15.0% (12.6%; 17.8%)	11.0% (8.9%; 13.8%)	9.8% (7.6%; 12.5%)	FU<10y
<b>IV</b>	4,737	23.6% (22.4%; 24.8%)	9.1% (8.3%; 10.0%)	4.9% (4.3%; 5.7%)	3.5% (2.9%; 4.1%)	2.9% (2.3%; 3.5%)	1.5% (1.0%; 2.3%)
<b>X/NA</b>	1,573	51.3% (48.8%; 53.9%)	36.9% (34.4%; 39.5%)	30.2% (27.8%; 32.8%)	27.1% (24.8%; 29.7%)	24.2% (21.8%; 26.9%)	18.7% (15.5%; 22.5%)
<b>Females</b>							
<b>All</b>	9,807	42.5% (41.5%; 43.5%)	25.7% (24.8%; 26.6%)	19.0% (18.2%; 19.9%)	16.0% (15.2%; 16.8%)	14.3% (13.5%; 15.2%)	11.8% (10.5%; 13.1%)
<b>I</b>	1,675	70.0% (67.7%; 72.3%)	52.3% (49.8%; 54.9%)	43.7% (41.1%; 46.5%)	39.2% (36.5%; 42.1%)	35.9% (33.0%; 39.0%)	33.2% (28.8%; 38.3%)
<b>II</b>	1,266	55.6% (52.8%; 58.5%)	34.2% (31.5%; 37.0%)	24.9% (22.4%; 27.7%)	20.2% (17.7%; 23.0%)	17.6% (15.0%; 20.5%)	15.8% (12.4%; 20.0%)
<b>III</b>	894	48.9% (45.7%; 52.4%)	24.2% (21.5%; 27.4%)	14.0% (11.7%; 16.8%)	9.4% (7.3%; 12.0%)	6.9% (4.9%; 9.8%)	5.2% (3.2%; 8.6%)
<b>IV</b>	4,373	23.8% (22.5%; 25.1%)	9.7% (8.8%; 10.6%)	5.0% (4.3%; 5.7%)	3.4% (2.8%; 4.0%)	2.5% (2.0%; 3.1%)	1.3% (0.8%; 2.0%)
<b>X/NA</b>	1,608	50.9% (48.4%; 53.4%)	35.8% (33.5%; 38.4%)	29.5% (27.2%; 32.0%)	26.1% (23.8%; 28.5%)	24.5% (22.2%; 27.0%)	20.0% (16.7%; 23.8%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<yyears in the table.

4.2.2. Pancreatic cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	20,021	43.0% (42.3%; 43.7%)	26.1% (25.5%; 26.7%)	19.5% (19.0%; 20.2%)	16.5% (16.0%; 17.1%)	14.7% (14.1%; 15.4%)	11.9% (11.1%; 12.9%)
<b>Males</b>							
<b>All</b>	10,214	43.4% (42.4%; 44.4%)	26.4% (25.6%; 27.4%)	20.1% (19.2%; 20.9%)	17.1% (16.2%; 17.9%)	15.2% (14.3%; 16.1%)	12.1% (10.8%; 13.5%)
<b>I</b>	676	90.6% (88.1%; 93.1%)	80.6% (77.2%; 84.1%)	74.5% (70.6%; 78.6%)	70.8% (66.5%; 75.3%)	65.8% (60.9%; 71.1%)	64.9% (54.7%; 77.0%)
<b>II</b>	1,224	78.5% (76.1%; 80.9%)	57.8% (54.9%; 60.9%)	43.2% (40.2%; 46.4%)	35.9% (32.9%; 39.2%)	30.8% (27.8%; 34.1%)	21.2% (17.4%; 25.9%)
<b>III</b>	584	75.8% (72.3%; 79.6%)	49.7% (45.5%; 54.2%)	37.9% (33.7%; 42.6%)	30.5% (26.3%; 35.3%)	25.1% (20.9%; 30.2%)	FU<10y
<b>IV</b>	1,282	29.7% (27.2%; 32.3%)	13.8% (12.0%; 15.9%)	8.4% (6.9%; 10.2%)	6.1% (4.7%; 7.8%)	5.5% (4.2%; 7.2%)	2.9% (1.8%; 4.8%)
<b>X/NA</b>	6,462	31.7% (30.6%; 32.9%)	15.3% (14.3%; 16.2%)	10.7% (9.9%; 11.6%)	8.9% (8.1%; 9.8%)	8.0% (7.2%; 8.9%)	6.3% (5.1%; 7.8%)
<b>Females</b>							
<b>All</b>	9,807	42.5% (41.5%; 43.5%)	25.7% (24.8%; 26.6%)	19.0% (18.2%; 19.9%)	16.0% (15.2%; 16.8%)	14.3% (13.5%; 15.2%)	11.8% (10.5%; 13.1%)
<b>I</b>	737	91.7% (89.6%; 93.9%)	83.0% (80.0%; 86.0%)	74.7% (71.2%; 78.4%)	70.1% (66.3%; 74.2%)	66.0% (61.7%; 70.5%)	60.0% (52.4%; 68.6%)
<b>II</b>	1,070	78.6% (76.1%; 81.2%)	54.0% (51.0%; 57.2%)	41.4% (38.4%; 44.8%)	34.3% (31.2%; 37.6%)	29.9% (26.9%; 33.3%)	20.3% (15.8%; 26.1%)
<b>III</b>	423	76.5% (72.4%; 80.8%)	49.6% (44.8%; 54.9%)	32.0% (27.4%; 37.4%)	23.9% (19.5%; 29.4%)	20.5% (16.1%; 26.2%)	FU<10y
<b>IV</b>	1,107	31.8% (29.2%; 34.7%)	15.4% (13.4%; 17.8%)	9.3% (7.7%; 11.3%)	6.6% (5.2%; 8.5%)	4.5% (3.3%; 6.3%)	1.5% (0.5%; 4.6%)
<b>X/NA</b>	6,479	30.5% (29.4%; 31.7%)	14.7% (13.9%; 15.7%)	9.7% (9.0%; 10.6%)	7.8% (7.1%; 8.6%)	7.1% (6.3%; 7.9%)	6.4% (5.2%; 7.7%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

#### 4.2.3. Pancreatic cancer survival by stage and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	20,021	43.0% (42.3%; 43.7%)	26.1% (25.5%; 26.7%)	19.5% (19.0%; 20.2%)	16.5% (16.0%; 17.1%)	14.7% (14.1%; 15.4%)	11.9% (11.1%; 12.9%)
<b>Males</b>							
<b>All</b>	10,214	43.4% (42.4%; 44.4%)	26.4% (25.6%; 27.4%)	20.1% (19.2%; 20.9%)	17.1% (16.2%; 17.9%)	15.2% (14.3%; 16.1%)	12.1% (10.8%; 13.5%)
<b>I</b>	1,316	75.6% (73.1%; 78.1%)	62.5% (59.7%; 65.5%)	58.9% (55.8%; 62.1%)	55.7% (52.3%; 59.2%)	52.5% (48.8%; 56.4%)	51.7% (44.4%; 60.2%)
<b>II</b>	1,799	66.2% (63.9%; 68.5%)	44.9% (42.5%; 47.4%)	32.7% (30.3%; 35.2%)	27.1% (24.9%; 29.6%)	23.0% (20.8%; 25.6%)	16.0% (13.2%; 19.4%)
<b>III</b>	1,297	58.3% (55.6%; 61.2%)	31.5% (28.9%; 34.3%)	21.4% (19.0%; 24.0%)	16.0% (13.8%; 18.6%)	13.4% (11.2%; 16.1%)	FU<10y
<b>IV</b>	4,922	24.1% (22.9%; 25.3%)	9.4% (8.6%; 10.3%)	5.2% (4.5%; 5.9%)	3.6% (3.0%; 4.2%)	3.0% (2.5%; 3.6%)	1.5% (1.0%; 2.3%)
<b>X/NA</b>	895	35.5% (32.3%; 38.9%)	22.9% (20.1%; 26.0%)	18.5% (15.9%; 21.6%)	16.9% (14.2%; 20.0%)	15.3% (12.5%; 18.7%)	11.8% (8.3%; 16.7%)
<b>Females</b>							
<b>All</b>	9,807	42.5% (41.5%; 43.5%)	25.7% (24.8%; 26.6%)	19.0% (18.2%; 19.9%)	16.0% (15.2%; 16.8%)	14.3% (13.5%; 15.2%)	11.8% (10.5%; 13.1%)
<b>I</b>	1,395	72.3% (69.9%; 74.9%)	60.1% (57.4%; 63.0%)	53.5% (50.6%; 56.5%)	50.6% (47.5%; 53.8%)	48.5% (45.3%; 51.9%)	46.3% (41.0%; 52.3%)
<b>II</b>	1,742	62.2% (59.8%; 64.6%)	39.3% (36.9%; 41.8%)	29.3% (27.1%; 31.8%)	24.4% (22.2%; 26.8%)	21.1% (18.8%; 23.5%)	14.9% (11.7%; 19.0%)
<b>III</b>	1,172	55.3% (52.5%; 58.3%)	29.4% (26.8%; 32.3%)	17.8% (15.6%; 20.4%)	12.2% (10.2%; 14.7%)	10.1% (8.0%; 12.7%)	8.5% (6.3%; 11.5%)
<b>IV</b>	4,550	24.3% (23.1%; 25.6%)	10.0% (9.1%; 10.9%)	5.2% (4.6%; 6.0%)	3.5% (2.9%; 4.1%)	2.5% (2.0%; 3.1%)	1.2% (0.7%; 1.9%)
<b>X/NA</b>	960	34.0% (31.0%; 37.2%)	21.4% (18.8%; 24.3%)	17.4% (15.0%; 20.2%)	14.6% (12.2%; 17.4%)	13.9% (11.5%; 16.7%)	12.3% (8.9%; 17.0%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

### 4.3. Pancreatic cancer survival: by tumour type and tumour stage

#### 4.3.1. Pancreatic cancer survival by type, stage and sex: number at risk and net survival probabilities, 2014-2023

type	Net Survival Probability, 2014-2023							
	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	Total	20,021	43.0% (42.3%; 43.7%)	26.1% (25.5%; 26.7%)	19.5% (19.0%; 20.2%)	16.5% (16.0%; 17.1%)	14.7% (14.1%; 15.4%)	11.9% (11.1%; 12.9%)
<b>Males</b>								
<b>Total</b>	All	10,214	43.4% (42.4%; 44.4%)	26.4% (25.6%; 27.4%)	20.1% (19.2%; 20.9%)	17.1% (16.2%; 17.9%)	15.2% (14.3%; 16.1%)	12.1% (10.8%; 13.5%)
	I	1,316	75.6% (73.1%; 78.1%)	62.5% (59.7%; 65.5%)	58.9% (55.8%; 62.1%)	55.7% (52.3%; 59.2%)	52.5% (48.8%; 56.4%)	51.7% (44.4%; 60.2%)
	II	1,799	66.2% (63.9%; 68.5%)	44.9% (42.5%; 47.4%)	32.7% (30.3%; 35.2%)	27.1% (24.9%; 29.6%)	23.0% (20.8%; 25.6%)	16.0% (13.2%; 19.4%)
	III	1,297	58.3% (55.6%; 61.2%)	31.5% (28.9%; 34.3%)	21.4% (19.0%; 24.0%)	16.0% (13.8%; 18.6%)	13.4% (11.2%; 16.1%)	FU<10y
	IV	4,922	24.1% (22.9%; 25.3%)	9.4% (8.6%; 10.3%)	5.2% (4.5%; 5.9%)	3.6% (3.0%; 4.2%)	3.0% (2.5%; 3.6%)	1.5% (1.0%; 2.3%)
	X/NA	895	35.5% (32.3%; 38.9%)	22.9% (20.1%; 26.0%)	18.5% (15.9%; 21.6%)	16.9% (14.2%; 20.0%)	15.3% (12.5%; 18.7%)	11.8% (8.3%; 16.7%)
<b>ADC</b>	All	7,756	41.2% (40.1%; 42.4%)	21.1% (20.2%; 22.1%)	13.7% (12.9%; 14.6%)	10.2% (9.5%; 11.1%)	8.1% (7.4%; 8.9%)	5.4% (4.5%; 6.5%)
	I	703	69.2% (65.6%; 72.9%)	48.5% (44.6%; 52.7%)	42.6% (38.6%; 47.0%)	38.3% (34.1%; 42.9%)	31.7% (27.4%; 36.8%)	32.2% (25.9%; 40.1%)
	II	1,490	65.9% (63.4%; 68.5%)	41.4% (38.8%; 44.2%)	27.8% (25.5%; 30.5%)	21.9% (19.6%; 24.4%)	17.7% (15.5%; 20.2%)	10.1% (7.7%; 13.2%)
	III	1,032	60.6% (57.6%; 63.8%)	29.2% (26.4%; 32.3%)	17.2% (14.8%; 20.0%)	10.7% (8.6%; 13.2%)	7.7% (5.8%; 10.1%)	FU<10y
	IV	3,948	23.8% (22.4%; 25.1%)	7.7% (6.9%; 8.7%)	3.4% (2.8%; 4.0%)	1.8% (1.4%; 2.4%)	1.2% (0.8%; 1.7%)	0.4% (0.1%; 0.9%)
	X/NA	583	28.5% (24.9%; 32.5%)	12.0% (9.5%; 15.2%)	6.9% (5.0%; 9.5%)	4.0% (2.5%; 6.4%)	3.3% (1.9%; 5.6%)	FU<10y
<b>NENs</b>	All	1,091	85.1% (82.9%; 87.5%)	79.3% (76.6%; 82.1%)	75.2% (72.2%; 78.4%)	73.5% (70.1%; 77.0%)	72.8% (69.1%; 76.7%)	64.5% (56.9%; 73.1%)
	I	405	97.1% (94.9%; 99.4%)	96.7% (93.9%; 99.6%)	97.2% (93.9%; 100.6%)	97.1% (92.9%; 101.4%)	97.5% (92.5%; 102.7%)	98.6% (84.1%; 115.5%)
	II	173	94.4% (90.3%; 98.6%)	91.2% (85.8%; 96.9%)	87.5% (80.9%; 94.8%)	86.7% (79.3%; 94.8%)	85.7% (76.9%; 95.5%)	83.9% (68.8%; 102.3%)
	III	107	94.8% (89.8%; 100.1%)	89.4% (82.3%; 97.0%)	86.5% (78.3%; 95.6%)	89.9% (81.3%; 99.3%)	88.2% (77.3%; 100.7%)	FU<10y
	IV	305	61.9% (56.5%; 67.8%)	46.0% (40.5%; 52.3%)	37.1% (31.7%; 43.4%)	31.7% (26.2%; 38.2%)	29.8% (24.3%; 36.5%)	17.9% (12.0%; 26.5%)
	X/NA	101	81.5% (73.8%; 90.0%)	79.9% (71.4%; 89.3%)	73.6% (64.0%; 84.5%)	71.4% (61.1%; 83.5%)	71.5% (60.3%; 85.0%)	56.5% (39.0%; 81.9%)



Net Survival Probability, 2014-2023								
type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Other and unspecified	All	1,386	23.1% (20.9%; 25.5%)	14.9% (13.0%; 17.1%)	12.6% (10.7%; 14.8%)	11.4% (9.4%; 13.7%)	10.1% (8.0%; 12.7%)	8.9% (5.6%; 14.2%)
	I	212	55.3% (48.5%; 63.0%)	44.0% (37.0%; 52.4%)	40.3% (33.0%; 49.2%)	34.9% (27.1%; 45.0%)	35.6% (27.1%; 46.7%)	29.3% (13.7%; 62.9%)
	II	136	33.6% (26.2%; 43.0%)	24.6% (17.8%; 33.9%)	17.5% (11.6%; 26.5%)	12.5% (7.2%; 21.8%)	8.4% (3.8%; 18.4%)	8.4% (3.5%; 20.1%)
	III	158	18.5% (13.2%; 26.1%)	7.2% (4.0%; 12.8%)	4.8% (2.3%; 10.3%)	2.8% (1.0%; 8.1%)	2.9% (1.0%; 8.5%)	FU<10y
	IV	669	8.8% (6.8%; 11.3%)	2.2% (1.3%; 3.7%)	0.9% (0.4%; 2.1%)	0.7% (0.2%; 1.9%)	0.7% (0.3%; 1.9%)	0.8% (0.3%; 2.2%)
	X/NA	211	32.6% (26.6%; 40.0%)	25.1% (19.4%; 32.7%)	23.9% (18.0%; 31.7%)	25.9% (19.4%; 34.7%)	20.6% (13.7%; 31.0%)	17.4% (9.1%; 33.4%)
Females								
Total	All	9,807	42.5% (41.5%; 43.5%)	25.7% (24.8%; 26.6%)	19.0% (18.2%; 19.9%)	16.0% (15.2%; 16.8%)	14.3% (13.5%; 15.2%)	11.8% (10.5%; 13.1%)
	I	1,395	72.3% (69.9%; 74.9%)	60.1% (57.4%; 63.0%)	53.5% (50.6%; 56.5%)	50.6% (47.5%; 53.8%)	48.5% (45.3%; 51.9%)	46.3% (41.0%; 52.3%)
	II	1,742	62.2% (59.8%; 64.6%)	39.3% (36.9%; 41.8%)	29.3% (27.1%; 31.8%)	24.4% (22.2%; 26.8%)	21.1% (18.8%; 23.5%)	14.9% (11.7%; 19.0%)
	III	1,172	55.3% (52.5%; 58.3%)	29.4% (26.8%; 32.3%)	17.8% (15.6%; 20.4%)	12.2% (10.2%; 14.7%)	10.1% (8.0%; 12.7%)	8.5% (6.3%; 11.5%)
	IV	4,550	24.3% (23.1%; 25.6%)	10.0% (9.1%; 10.9%)	5.2% (4.6%; 6.0%)	3.5% (2.9%; 4.1%)	2.5% (2.0%; 3.1%)	1.2% (0.7%; 1.9%)
	X/NA	960	34.0% (31.0%; 37.2%)	21.4% (18.8%; 24.3%)	17.4% (15.0%; 20.2%)	14.6% (12.2%; 17.4%)	13.9% (11.5%; 16.7%)	12.3% (8.9%; 17.0%)
ADC	All	7,323	42.3% (41.1%; 43.5%)	22.0% (21.0%; 23.0%)	13.8% (13.0%; 14.7%)	10.3% (9.5%; 11.1%)	8.7% (7.9%; 9.5%)	5.7% (4.6%; 6.9%)
	I	794	70.1% (66.8%; 73.5%)	52.0% (48.4%; 55.8%)	41.7% (38.0%; 45.7%)	36.6% (32.9%; 40.7%)	33.2% (29.4%; 37.6%)	24.6% (18.9%; 32.1%)
	II	1,420	63.3% (60.8%; 66.0%)	37.4% (34.9%; 40.2%)	26.0% (23.6%; 28.6%)	20.2% (18.0%; 22.7%)	17.2% (15.0%; 19.6%)	11.2% (8.4%; 14.9%)
	III	976	58.1% (55.0%; 61.4%)	29.1% (26.3%; 32.3%)	16.2% (13.9%; 19.0%)	10.1% (8.0%; 12.7%)	8.0% (6.0%; 10.6%)	5.7% (3.7%; 8.8%)
	IV	3,564	25.7% (24.3%; 27.2%)	9.0% (8.0%; 10.0%)	3.5% (2.9%; 4.2%)	1.6% (1.2%; 2.2%)	0.9% (0.6%; 1.4%)	0.3% (0.1%; 0.7%)
	X/NA	569	27.8% (24.3%; 31.9%)	11.1% (8.7%; 14.1%)	5.3% (3.7%; 7.7%)	3.1% (1.9%; 5.1%)	2.5% (1.4%; 4.5%)	FU<10y
NENs	All	880	87.0% (84.7%; 89.4%)	82.6% (79.9%; 85.4%)	79.6% (76.6%; 82.7%)	77.5% (74.2%; 80.9%)	73.9% (70.2%; 77.8%)	69.7% (61.8%; 78.7%)
	I	360	97.1% (95.0%; 99.3%)	95.9% (93.2%; 98.7%)	94.6% (91.3%; 98.0%)	95.9% (92.5%; 99.5%)	94.1% (89.7%; 98.7%)	98.6% (87.4%; 111.1%)
	II	145	90.3% (85.2%; 95.6%)	87.2% (81.3%; 93.6%)	84.2% (77.5%; 91.5%)	82.1% (74.6%; 90.3%)	76.3% (67.6%; 86.3%)	70.3% (58.5%; 84.4%)
	III	46	N<50	N<50	N<50	N<50	N<50	N<50
	IV	220	66.4% (60.3%; 73.1%)	53.9% (47.5%; 61.2%)	47.1% (40.6%; 54.7%)	41.4% (34.8%; 49.2%)	33.6% (27.1%; 41.7%)	18.6% (10.9%; 31.8%)

Net Survival Probability, 2014-2023								
type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	109	89.7% (83.7%; 96.1%)	87.5% (80.7%; 95.0%)	86.2% (78.6%; 94.6%)	82.2% (73.4%; 92.1%)	83.9% (74.5%; 94.4%)	77.6% (55.7%; 108.3%)
Other and unspecified	All	1,619	19.2% (17.3%; 21.3%)	11.9% (10.3%; 13.7%)	9.8% (8.3%; 11.6%)	8.4% (6.8%; 10.3%)	7.4% (5.7%; 9.6%)	8.9% (6.7%; 11.8%)
	I	243	43.5% (37.3%; 50.6%)	33.6% (27.6%; 41.0%)	31.3% (25.0%; 39.2%)	29.9% (23.0%; 38.7%)	32.1% (24.8%; 41.7%)	42.7% (32.0%; 56.9%)
	II	178	29.5% (23.3%; 37.4%)	14.4% (9.7%; 21.2%)	11.8% (7.5%; 18.6%)	12.5% (7.7%; 20.2%)	8.4% (3.7%; 19.4%)	FU<10y
	III	150	26.3% (20.0%; 34.7%)	13.3% (8.7%; 20.4%)	6.2% (3.1%; 12.3%)	2.5% (0.8%; 7.7%)	1.1% (0.2%; 6.0%)	FU<10y
	IV	766	5.7% (4.2%; 7.6%)	2.4% (1.5%; 3.8%)	0.9% (0.4%; 2.2%)	0.5% (0.1%; 1.5%)	0.2% (0.0%; 1.1%)	FU<10y
	X/NA	282	24.9% (20.1%; 30.8%)	16.8% (12.7%; 22.2%)	15.5% (11.3%; 21.1%)	11.8% (7.8%; 17.9%)	9.7% (6.0%; 15.6%)	9.3% (5.2%; 16.4%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

## 5. CANCER SURVIVAL TRENDS



### 5.1. Pancreatic cancer survival trends: by tumour stage

#### 5.1.1. Pancreatic cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	All	2,942	33.2% (31.5%; 35.0%)	12.7% (11.5%; 14.1%)	9.2% (8.1%; 10.4%)	2,706	34.0% (32.3%; 35.9%)	11.4% (10.2%; 12.7%)	8.5% (7.4%; 9.7%)
	I	174	62.4% (55.3%; 70.4%)	36.8% (29.8%; 45.5%)	31.3% (24.4%; 40.0%)	171	65.6% (58.6%; 73.5%)	37.6% (30.7%; 46.0%)	30.2% (23.7%; 38.6%)
	II	604	58.8% (54.9%; 63.0%)	23.2% (20.0%; 27.1%)	14.8% (12.0%; 18.2%)	557	56.9% (52.9%; 61.3%)	17.3% (14.3%; 20.8%)	11.9% (9.3%; 15.1%)
	III	198	35.3% (29.1%; 42.8%)	7.2% (4.3%; 12.0%)	2.9% (1.3%; 6.7%)	236	33.2% (27.6%; 39.9%)	5.3% (3.1%; 9.1%)	1.8% (0.7%; 4.5%)
	IV	1,115	19.4% (17.2%; 21.9%)	4.2% (3.1%; 5.6%)	2.7% (1.9%; 3.9%)	932	20.0% (17.6%; 22.8%)	3.8% (2.7%; 5.3%)	2.5% (1.7%; 3.9%)
	X/NA	852	26.9% (24.0%; 30.1%)	12.9% (10.7%; 15.5%)	10.7% (8.6%; 13.2%)	810	28.1% (25.1%; 31.5%)	12.3% (10.1%; 14.9%)	10.4% (8.3%; 12.9%)
2009-2013	All	3,929	35.9% (34.4%; 37.5%)	14.3% (13.2%; 15.5%)	11.2% (10.2%; 12.3%)	3,701	36.7% (35.1%; 38.3%)	15.2% (14.0%; 16.4%)	11.2% (10.2%; 12.3%)
	I	335	70.5% (65.4%; 75.9%)	49.1% (43.5%; 55.5%)	44.3% (38.5%; 51.1%)	356	70.6% (65.7%; 75.8%)	51.6% (46.2%; 57.5%)	45.5% (40.0%; 51.7%)
	II	889	57.9% (54.7%; 61.4%)	24.4% (21.6%; 27.5%)	17.9% (15.3%; 20.9%)	801	57.8% (54.3%; 61.4%)	25.2% (22.3%; 28.6%)	15.8% (13.3%; 18.8%)
	III	296	36.8% (31.6%; 42.9%)	6.6% (4.3%; 10.3%)	4.2% (2.4%; 7.5%)	311	38.8% (33.7%; 44.7%)	5.8% (3.7%; 9.1%)	3.9% (2.2%; 6.9%)
	IV	1,554	20.2% (18.3%; 22.3%)	4.2% (3.3%; 5.4%)	2.0% (1.4%; 2.9%)	1,404	22.0% (19.9%; 24.3%)	4.5% (3.5%; 5.7%)	2.6% (1.9%; 3.7%)
	X/NA	856	27.7% (24.8%; 31.0%)	11.2% (9.1%; 13.7%)	10.6% (8.5%; 13.1%)	830	25.9% (23.0%; 29.1%)	11.4% (9.3%; 14.0%)	9.3% (7.3%; 11.7%)
2014-2018	All	4,683	39.6% (38.2%; 41.1%)	17.2% (16.1%; 18.4%)	12.5% (11.5%; 13.7%)	4,517	39.8% (38.3%; 41.3%)	16.8% (15.7%; 18.0%)	12.9% (11.9%; 14.0%)
	I	424	73.1% (68.7%; 77.8%)	58.0% (52.9%; 63.6%)	51.3% (45.7%; 57.5%)	489	68.5% (64.3%; 73.0%)	53.7% (49.1%; 58.8%)	50.2% (45.4%; 55.5%)
	II	940	65.8% (62.7%; 69.0%)	29.9% (26.9%; 33.2%)	19.2% (16.6%; 22.2%)	918	61.6% (58.5%; 65.0%)	27.1% (24.3%; 30.3%)	19.8% (17.2%; 22.8%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	458	49.7% (45.2%; 54.7%)	13.8% (10.9%; 17.5%)	8.9% (6.5%; 12.3%)	415	51.6% (46.9%; 56.8%)	13.8% (10.8%; 17.7%)	7.4% (5.1%; 10.7%)
	IV	2,222	21.7% (20.0%; 23.5%)	4.7% (3.9%; 5.7%)	2.6% (2.0%; 3.5%)	1,995	22.7% (20.9%; 24.6%)	4.6% (3.8%; 5.7%)	2.1% (1.5%; 2.8%)
	X/NA	644	33.9% (30.3%; 37.9%)	17.0% (14.1%; 20.5%)	14.0% (11.0%; 17.8%)	706	33.1% (29.7%; 36.9%)	14.4% (11.9%; 17.4%)	12.3% (9.8%; 15.3%)
2019-2023	All	5,532	46.7% (45.3%; 48.0%)	22.7% (21.5%; 24.0%)	18.1% (16.7%; 19.5%)	5,290	44.7% (43.4%; 46.1%)	21.0% (19.8%; 22.3%)	15.3% (14.0%; 16.8%)
	I	892	76.7% (73.8%; 79.8%)	59.6% (55.9%; 63.6%)	53.3% (48.3%; 58.8%)	906	74.4% (71.5%; 77.5%)	53.1% (49.4%; 57.0%)	46.7% (42.2%; 51.6%)
	II	859	66.6% (63.4%; 70.0%)	36.1% (32.6%; 40.0%)	29.9% (26.0%; 34.4%)	824	62.7% (59.4%; 66.3%)	32.2% (28.8%; 36.1%)	22.5% (18.4%; 27.5%)
	III	839	63.0% (59.7%; 66.5%)	26.1% (22.9%; 29.7%)	16.2% (13.1%; 20.2%)	757	57.4% (53.9%; 61.1%)	20.4% (17.3%; 23.9%)	12.4% (9.4%; 16.3%)
	IV	2,700	26.1% (24.4%; 27.8%)	5.5% (4.6%; 6.6%)	3.5% (2.6%; 4.5%)	2,555	25.5% (23.9%; 27.3%)	5.7% (4.8%; 6.8%)	3.0% (2.2%; 4.0%)
	X/NA	251	39.5% (33.7%; 46.4%)	22.6% (17.4%; 29.5%)	19.0% (13.4%; 27.0%)	254	36.4% (30.7%; 43.0%)	26.8% (21.4%; 33.5%)	17.2% (11.8%; 25.0%)

## 5.2. Pancreatic cancer survival trends: by tumour type and tumour stage

### 5.2.1. Pancreatic cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2023

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
ADC	2004-2008	All	2,305	32.3% (30.4%; 34.3%)	9.5% (8.3%; 10.9%)	6.0% (5.0%; 7.2%)	2,039	34.9% (32.8%; 37.0%)	8.0% (6.9%; 9.3%)	5.0% (4.1%; 6.1%)
		I	132	64.5% (56.5%; 73.7%)	33.5% (25.8%; 43.5%)	25.7% (18.6%; 35.5%)	111	68.0% (59.6%; 77.6%)	31.9% (24.1%; 42.3%)	20.9% (14.3%; 30.6%)
		II	537	60.2% (56.1%; 64.7%)	22.2% (18.8%; 26.2%)	13.4% (10.6%; 16.8%)	484	60.6% (56.3%; 65.2%)	17.1% (14.0%; 20.9%)	11.4% (8.8%; 14.8%)
		III	156	37.6% (30.6%; 46.2%)	6.4% (3.4%; 11.8%)	3.0% (1.2%; 7.6%)	192	38.1% (31.8%; 45.7%)	6.0% (3.4%; 10.5%)	1.6% (0.6%; 4.6%)
		IV	893	18.5% (16.1%; 21.2%)	2.0% (1.3%; 3.2%)	1.4% (0.8%; 2.4%)	725	19.6% (16.9%; 22.8%)	1.7% (1.0%; 3.0%)	0.9% (0.4%; 1.9%)
		X/NA	587	19.2% (16.3%; 22.8%)	4.7% (3.2%; 6.9%)	2.7% (1.6%; 4.5%)	527	24.2% (20.7%; 28.2%)	4.1% (2.7%; 6.2%)	2.9% (1.7%; 4.8%)
	2009-2013	All	3,037	33.9% (32.2%; 35.7%)	9.3% (8.3%; 10.4%)	6.2% (5.3%; 7.2%)	2,794	35.1% (33.4%; 37.0%)	10.8% (9.6%; 12.0%)	6.2% (5.4%; 7.3%)
		I	186	61.2% (54.3%; 69.1%)	30.5% (24.0%; 38.6%)	22.9% (16.9%; 31.0%)	190	66.2% (59.5%; 73.6%)	40.1% (33.4%; 48.3%)	28.8% (22.5%; 36.8%)
		II	772	57.9% (54.4%; 61.7%)	20.5% (17.7%; 23.7%)	13.0% (10.6%; 15.8%)	699	57.8% (54.2%; 61.7%)	23.1% (20.1%; 26.6%)	12.6% (10.2%; 15.5%)
		III	234	39.9% (34.0%; 46.9%)	6.1% (3.7%; 10.2%)	3.0% (1.4%; 6.3%)	247	40.5% (34.8%; 47.2%)	4.7% (2.6%; 8.2%)	2.6% (1.2%; 5.6%)
		IV	1,208	19.0% (16.9%; 21.4%)	1.8% (1.2%; 2.8%)	0.8% (0.4%; 1.5%)	1,071	20.8% (18.5%; 23.4%)	2.0% (1.3%; 3.0%)	0.6% (0.3%; 1.4%)
		X/NA	637	22.8% (19.7%; 26.4%)	4.9% (3.4%; 7.1%)	4.6% (3.1%; 6.8%)	587	21.8% (18.6%; 25.5%)	5.1% (3.5%; 7.4%)	3.1% (1.9%; 5.0%)
	2014-2018	All	3,605	38.0% (36.4%; 39.6%)	12.1% (11.0%; 13.3%)	6.8% (6.0%; 7.8%)	3,337	40.0% (38.3%; 41.7%)	12.0% (10.9%; 13.2%)	7.8% (6.9%; 8.8%)
		I	207	67.9% (61.5%; 75.0%)	44.1% (37.2%; 52.2%)	32.7% (26.1%; 41.1%)	259	65.1% (59.3%; 71.5%)	40.1% (34.2%; 47.1%)	32.9% (27.1%; 40.0%)
		II	813	66.8% (63.5%; 70.3%)	27.2% (24.1%; 30.6%)	15.6% (13.1%; 18.5%)	777	63.6% (60.2%; 67.2%)	25.3% (22.3%; 28.7%)	17.5% (14.9%; 20.7%)
		III	368	54.1% (49.1%; 59.6%)	12.3% (9.3%; 16.3%)	6.0% (3.9%; 9.2%)	343	53.4% (48.3%; 59.1%)	12.2% (9.1%; 16.3%)	5.8% (3.7%; 9.1%)
		IV	1,794	20.4% (18.6%; 22.3%)	2.9% (2.2%; 3.8%)	0.9% (0.6%; 1.5%)	1,535	23.7% (21.7%; 26.0%)	2.7% (2.0%; 3.7%)	0.8% (0.4%; 1.4%)
		X/NA	423	28.4% (24.3%; 33.2%)	6.4% (4.4%; 9.5%)	3.0% (1.6%; 5.6%)	423	29.4% (25.3%; 34.2%)	3.8% (2.4%; 6.2%)	1.5% (0.6%; 3.4%)
	2019-2023	All	4,151	44.1% (42.6%; 45.7%)	15.2% (14.0%; 16.5%)	9.8% (8.6%; 11.1%)	3,986	44.2% (42.6%; 45.8%)	15.5% (14.3%; 16.8%)	9.3% (8.1%; 10.7%)
		I	496	69.7% (65.5%; 74.2%)	42.2% (37.5%; 47.6%)	31.4% (25.5%; 38.7%)	535	72.4% (68.5%; 76.6%)	42.4% (37.9%; 47.4%)	33.3% (28.3%; 39.2%)

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	677	64.8% (61.2%; 68.7%)	28.9% (25.3%; 33.1%)	22.4% (18.5%; 27.1%)	643	63.0% (59.3%; 67.0%)	26.8% (23.2%; 31.1%)	15.7% (12.2%; 20.3%)
		III	664	64.3% (60.6%; 68.2%)	20.4% (17.2%; 24.3%)	8.6% (6.0%; 12.4%)	633	60.7% (56.9%; 64.7%)	18.7% (15.5%; 22.6%)	9.3% (6.4%; 13.7%)
		IV	2,154	26.6% (24.7%; 28.5%)	3.7% (2.9%; 4.7%)	1.7% (1.1%; 2.7%)	2,029	27.1% (25.2%; 29.2%)	4.1% (3.3%; 5.3%)	0.9% (0.4%; 1.8%)
		X/NA	160	28.8% (22.4%; 37.0%)	8.2% (4.6%; 14.7%)	4.5% (1.9%; 11.1%)	146	23.2% (17.1%; 31.3%)	10.6% (6.5%; 17.5%)	6.5% (3.3%; 13.0%)
NENs	2004-2008	All	171	89.0% (84.0%; 94.4%)	79.1% (72.3%; 86.5%)	72.1% (64.2%; 81.0%)	158	87.2% (81.8%; 92.9%)	78.6% (71.8%; 86.0%)	74.2% (66.7%; 82.6%)
		I	20	N<50	N<50	N<50	28	N<50	N<50	N<50
		II	19	N<50	N<50	N<50	12	N<50	N<50	N<50
		III	3	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	47	N<50	N<50	N<50	42	N<50	N<50	N<50
		X/NA	82	93.9% (87.8%; 100.4%)	87.7% (78.8%; 97.7%)	85.7% (75.2%; 97.7%)	74	94.6% (88.9%; 100.5%)	91.9% (84.4%; 100.1%)	88.3% (79.0%; 98.7%)
	2009-2013	All	328	84.0% (79.9%; 88.3%)	72.4% (67.1%; 78.0%)	66.2% (60.4%; 72.5%)	269	89.8% (86.0%; 93.7%)	76.6% (71.4%; 82.3%)	71.3% (65.5%; 77.6%)
		I	95	96.5% (91.9%; 101.2%)	93.6% (86.9%; 100.7%)	92.7% (84.5%; 101.7%)	96	98.8% (95.8%; 101.8%)	93.0% (87.0%; 99.4%)	95.1% (88.9%; 101.6%)
		II	61	93.9% (87.2%; 101.1%)	90.3% (80.9%; 100.7%)	89.5% (78.3%; 102.4%)	36	N<50	N<50	N<50
		III	7	N<50	N<50	N<50	4	N<50	N<50	N<50
		IV	99	62.9% (53.8%; 73.4%)	38.7% (29.9%; 50.1%)	21.7% (14.5%; 32.3%)	75	73.1% (63.6%; 84.1%)	45.1% (34.8%; 58.4%)	30.2% (20.8%; 43.7%)
		X/NA	66	88.3% (80.2%; 97.1%)	77.2% (66.4%; 89.9%)	73.2% (61.2%; 87.4%)	58	92.4% (85.4%; 100.0%)	83.4% (73.4%; 94.8%)	80.3% (69.2%; 93.1%)
	2014-2018	All	425	82.8% (79.1%; 86.8%)	70.4% (65.6%; 75.5%)	68.2% (62.9%; 74.0%)	395	86.4% (82.9%; 90.0%)	78.7% (74.3%; 83.3%)	72.4% (67.4%; 77.8%)
		I	143	94.5% (90.1%; 99.1%)	91.2% (84.8%; 98.0%)	91.4% (83.7%; 99.9%)	145	97.6% (94.7%; 100.7%)	96.9% (92.7%; 101.3%)	96.5% (91.0%; 102.2%)
		II	60	90.3% (82.4%; 98.9%)	82.4% (71.7%; 94.7%)	80.1% (67.2%; 95.3%)	61	86.2% (77.7%; 95.7%)	76.4% (65.8%; 88.7%)	67.5% (55.7%; 81.9%)
		III	20	N<50	N<50	N<50	13	N<50	N<50	N<50
		IV	132	65.8% (57.9%; 74.7%)	38.3% (30.5%; 48.1%)	30.4% (23.0%; 40.2%)	101	66.0% (57.3%; 76.1%)	47.2% (38.1%; 58.3%)	29.0% (21.0%; 39.8%)
		X/NA	70	82.1% (73.1%; 92.2%)	74.5% (63.5%; 87.5%)	76.4% (64.1%; 91.0%)	75	92.3% (85.9%; 99.2%)	86.2% (77.1%; 96.4%)	86.7% (76.1%; 98.8%)
	2019-2023	All	666	86.6% (83.8%; 89.5%)	78.6% (74.7%; 82.6%)	76.3% (71.1%; 81.8%)	485	87.6% (84.5%; 90.8%)	80.5% (76.4%; 84.8%)	76.3% (70.8%; 82.3%)

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	262	98.5% (96.1%; 101.0%)	101.3% (98.0%; 104.7%)	101.7% (94.6%; 109.2%)	215	96.8% (94.0%; 99.7%)	92.7% (87.8%; 97.8%)	91.3% (83.7%; 99.6%)
		II	113	96.6% (92.1%; 101.2%)	89.8% (81.2%; 99.2%)	90.0% (79.6%; 101.7%)	84	93.3% (87.4%; 99.5%)	91.0% (83.3%; 99.4%)	88.6% (78.7%; 99.7%)
		III	87	95.3% (90.0%; 100.9%)	86.8% (77.8%; 96.9%)	87.9% (75.7%; 102.0%)	33	N<50	N<50	N<50
		IV	173	58.9% (51.9%; 67.0%)	36.3% (29.3%; 45.1%)	29.6% (21.9%; 40.2%)	119	66.7% (58.6%; 76.0%)	47.2% (38.3%; 58.2%)	42.0% (32.5%; 54.4%)
		X/NA	31	N<50	N<50	N<50	34	N<50	N<50	N<50
Other and unspecified	2004-2008	All	467	17.5% (14.3%; 21.5%)	4.3% (2.7%; 6.8%)	1.8% (0.9%; 3.8%)	510	14.4% (11.5%; 17.9%)	4.1% (2.6%; 6.6%)	2.1% (1.0%; 4.2%)
		I	22	N<50	N<50	N<50	32	N<50	N<50	N<50
		II	48	N<50	N<50	N<50	62	22.3% (14.0%; 35.7%)	6.7% (2.5%; 17.8%)	4.0% (1.0%; 16.3%)
		III	39	N<50	N<50	N<50	42	N<50	N<50	N<50
		IV	175	8.4% (5.1%; 13.7%)	FU<3y	FU<3y	165	8.8% (5.4%; 14.4%)	1.6% (0.5%; 5.3%)	0.7% (0.1%; 3.8%)
		X/NA	183	21.4% (16.1%; 28.4%)	5.6% (3.0%; 10.6%)	2.7% (1.0%; 7.0%)	209	14.4% (10.2%; 20.4%)	4.9% (2.5%; 9.4%)	1.7% (0.5%; 5.4%)
	2009-2013	All	566	18.6% (15.6%; 22.2%)	7.3% (5.3%; 10.1%)	6.3% (4.4%; 9.1%)	639	21.3% (18.3%; 24.9%)	8.5% (6.5%; 11.3%)	7.6% (5.5%; 10.5%)
		I	54	56.5% (43.9%; 72.6%)	35.0% (23.3%; 52.5%)	33.0% (20.8%; 52.2%)	70	44.2% (33.5%; 58.3%)	26.6% (17.0%; 41.5%)	23.5% (13.9%; 39.5%)
		II	57	18.3% (10.5%; 32.0%)	6.1% (2.2%; 16.9%)	6.7% (2.4%; 18.7%)	66	33.9% (23.8%; 48.2%)	11.3% (5.4%; 23.6%)	13.6% (6.5%; 28.3%)
		III	55	17.1% (9.6%; 30.4%)	2.2% (0.5%; 10.0%)	2.4% (0.5%; 11.2%)	60	31.1% (21.3%; 45.4%)	7.4% (3.1%; 18.0%)	6.1% (2.2%; 16.9%)
		IV	247	8.7% (5.8%; 13.1%)	2.1% (0.8%; 5.1%)	FU<5y	258	12.0% (8.6%; 16.7%)	3.0% (1.4%; 6.1%)	2.8% (1.3%; 6.0%)
		X/NA	153	22.0% (16.2%; 30.0%)	8.5% (4.9%; 14.8%)	8.3% (4.7%; 14.7%)	185	18.2% (13.2%; 24.9%)	9.1% (5.5%; 15.0%)	6.9% (3.7%; 12.8%)
	2014-2018	All	658	20.6% (17.6%; 24.1%)	10.4% (8.1%; 13.4%)	8.0% (5.6%; 11.3%)	792	15.8% (13.4%; 18.6%)	6.5% (4.9%; 8.7%)	5.1% (3.5%; 7.2%)
		I	74	46.5% (35.7%; 60.5%)	33.3% (22.7%; 48.8%)	26.2% (15.7%; 43.6%)	85	29.4% (21.0%; 41.3%)	21.8% (14.1%; 33.7%)	23.6% (15.3%; 36.4%)
		II	67	31.7% (22.0%; 45.7%)	16.0% (8.7%; 29.3%)	8.9% (3.4%; 22.9%)	81	23.6% (15.8%; 35.3%)	7.5% (3.4%; 16.5%)	5.2% (1.9%; 14.4%)
		III	70	14.7% (8.2%; 26.2%)	1.6% (0.3%; 7.6%)	1.8% (0.4%; 8.3%)	59	33.4% (23.2%; 48.2%)	7.1% (2.8%; 17.9%)	FU<5y
		IV	296	9.8% (6.9%; 14.0%)	0.7% (0.2%; 2.6%)	0.8% (0.2%; 2.7%)	359	5.9% (3.9%; 8.9%)	0.6% (0.2%; 2.0%)	FU<5y
		X/NA	151	26.9% (20.4%; 35.3%)	19.9% (13.8%; 28.7%)	15.9% (9.5%; 26.9%)	208	19.3% (14.5%; 25.7%)	10.0% (6.4%; 15.7%)	7.5% (4.3%; 13.2%)

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	2019-2023	All	728	25.3% (22.2%; 28.8%)	14.6% (11.9%; 17.9%)	12.7% (9.8%; 16.6%)	827	22.5% (19.7%; 25.7%)	13.3% (10.8%; 16.4%)	9.6% (6.3%; 14.5%)
		I	138	60.0% (51.8%; 69.5%)	44.0% (34.9%; 55.5%)	41.6% (30.7%; 56.2%)	158	51.0% (43.3%; 60.2%)	36.3% (28.1%; 47.1%)	36.6% (26.1%; 51.3%)
		II	69	35.4% (25.5%; 49.2%)	18.6% (10.6%; 32.7%)	8.6% (3.1%; 24.2%)	97	34.4% (25.8%; 45.8%)	15.8% (9.2%; 27.1%)	11.3% (3.6%; 34.9%)
		III	88	21.7% (14.4%; 32.6%)	8.3% (3.9%; 17.4%)	FU<5y	91	21.8% (14.7%; 32.3%)	6.2% (2.5%; 15.2%)	2.1% (0.4%; 9.9%)
		IV	373	8.0% (5.6%; 11.3%)	1.1% (0.4%; 3.3%)	0.6% (0.2%; 2.6%)	407	5.5% (3.7%; 8.3%)	1.2% (0.4%; 3.5%)	0.6% (0.1%; 2.6%)
		X/NA	60	47.1% (35.3%; 62.7%)	33.9% (22.0%; 52.2%)	38.1% (24.7%; 58.7%)	74	40.7% (30.5%; 54.3%)	31.7% (21.4%; 47.0%)	11.0% (3.7%; 33.2%)



## 6. CANCER MORTALITY



### 6.1. Pancreatic cancer mortality: by region

6.1.1. Pancreatic cancer mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	0	0	0	1	3	5	13	32	56	100	114	163	156	124	86	37	9	899	17.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[1.3]	[3.4]	[8.0]	[13.9]	[27.5]	[37.2]	[61.5]	[89.6]	[94.9]	[110.7]	[131.8]	[165.0]	[15.8]	(16.5; 18.8)
Brussels	0	0	0	0	0	0	0	0	1	4	5	2	8	8	13	8	13	6	4	0	72	19.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[9.2]	[12.5]	[5.9]	[29.3]	[38.5]	[77.8]	[69.6]	[153.8]	[118.7]	[183.9]	[0.0]	[12.0]	(15.0; 24.3)
Flanders	0	0	0	0	0	0	1	2	2	4	13	26	47	61	100	97	66	55	25	5	504	15.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[0.9]	[1.9]	[5.6]	[10.6]	[21.3]	[32.5]	[61.8]	[85.0]	[76.5]	[106.4]	[136.4]	[139.6]	[15.3]	(14.4; 17.2)
Wallonia	0	0	0	0	0	0	0	1	2	5	14	28	45	45	50	51	45	25	8	4	323	21.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.7]	[4.1]	[11.3]	[22.4]	[39.2]	[46.0]	[57.9]	[105.1]	[125.2]	[119.4]	[105.6]	[284.5]	[18.1]	(18.7; 23.4)
Females																						
Belgium	0	0	0	0	0	0	1	1	2	12	25	43	74	106	169	149	170	158	70	25	1,005	15.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[3.2]	[6.4]	[10.7]	[19.9]	[32.5]	[57.0]	[69.9]	[91.9]	[116.9]	[105.6]	[130.0]	[17.2]	(14.3; 16.2)
Brussels	0	0	0	0	0	0	0	0	0	1	4	2	4	10	6	10	13	9	12	1	72	13.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.5]	[10.8]	[6.0]	[13.5]	[40.8]	[27.8]	[61.5]	[94.9]	[88.6]	[209.1]	[51.1]	[11.6]	(10.5; 16.9)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	1	0	2	6	11	18	49	64	99	81	117	90	41	16	595	14.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[2.9]	[4.8]	[7.5]	[22.2]	[33.1]	[56.9]	[60.8]	[100.8]	[105.9]	[102.2]	[142.5]	[17.7]	(13.6; 16.0)
Wallonia	0	0	0	0	0	0	0	1	0	5	10	23	21	32	64	58	40	59	17	8	338	16.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[4.1]	[8.1]	[18.0]	[17.3]	[29.4]	[63.5]	[91.0]	[72.5]	[147.3]	[83.2]	[132.4]	[18.1]	(14.7; 18.3)

## 7. CANCER MORTALITY TRENDS



### 7.1. Pancreatic cancer mortality trends: by region

7.1.1. Pancreatic cancer mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	679	723	682	728	767	707	796	795	788	823	788	815	856	897	946	843	893	899	-0.2 (-0.5; 0.2)	2004-2021
	<b>CR</b>	13.3	14.1	13.3	14.1	14.7	13.4	15.0	14.8	14.6	15.1	14.4	14.8	15.5	16.1	16.9	15.0	15.8	15.8		
	<b>ESR2013</b>	18.3	18.7	17.7	18.3	19.1	17.2	18.3	18.6	17.7	18.3	17.1	17.4	18.1	18.8	19.4	17.0	17.5	17.6		
Brussels	<b>N</b>	56	58	58	66	81	60	61	63	68	61	57	69	73	62	67	61	63	72	-0.5 (-1.6; 0.6)	2004-2021
	<b>CR</b>	11.7	12.0	11.8	13.3	16.0	11.6	11.6	11.6	12.3	10.9	10.1	12.0	12.6	10.6	11.4	10.3	10.5	12.0		
	<b>ESR2013</b>	17.8	17.9	18.2	21.2	26.6	19.2	17.8	18.6	21.0	17.6	16.3	19.6	20.6	17.8	17.8	16.9	17.0	19.7		
Flanders	<b>N</b>	375	422	403	407	447	423	468	461	452	491	446	477	486	535	584	540	546	504	0.0 (-0.5; 0.5)	2004-2021
	<b>CR</b>	12.6	14.2	13.4	13.5	14.7	13.8	15.2	14.8	14.4	15.6	14.1	15.0	15.2	16.6	18.0	16.6	16.6	15.3		
	<b>ESR2013</b>	16.7	17.7	17.2	16.5	18.0	16.4	17.6	17.3	16.1	17.6	15.7	16.3	16.5	18.0	19.3	17.3	17.2	15.8		
Wallonia	<b>N</b>	248	243	221	255	239	224	267	271	268	271	285	269	297	300	295	242	284	323	-0.4 (-1.1; 0.3)	2004-2021
	<b>CR</b>	15.1	14.7	13.3	15.3	14.2	13.3	15.7	15.8	15.5	15.6	16.4	15.4	16.9	17.0	16.7	13.6	15.9	18.1		
	<b>ESR2013</b>	21.7	21.0	18.7	21.1	19.0	18.3	20.0	21.2	20.2	20.1	20.1	19.2	20.7	20.9	19.8	16.2	18.5	21.0		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Pancreatic cancer mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	630	731	735	740	749	737	806	854	799	839	859	895	855	947	901	946	960	1,005	1.0 (0.6; 1.3)	2004-2021
	<b>CR</b>	11.9	13.7	13.7	13.7	13.8	13.4	14.6	15.3	14.2	14.8	15.1	15.7	14.9	16.5	15.6	16.3	16.5	17.2		
	<b>ESR2013</b>	11.8	13.6	13.3	13.4	13.1	12.8	14.0	14.4	13.3	13.9	14.1	14.4	13.7	15.0	14.2	14.7	14.6	15.2		
Brussels	<b>N</b>	62	74	79	65	62	95	69	65	85	81	71	75	70	77	75	88	55	72	-0.1 (-1.4; 1.2)	2004-2021
	<b>CR</b>	11.9	14.1	14.9	12.2	11.4	17.2	12.3	11.3	14.5	13.7	11.9	12.4	11.5	12.6	12.3	14.3	8.9	11.6		
	<b>ESR2013</b>	12.4	15.0	15.2	13.4	11.9	18.5	13.6	12.9	16.3	14.9	13.6	14.2	13.6	15.8	14.7	16.0	10.6	13.7		
Flanders	<b>N</b>	346	407	415	408	433	427	468	473	456	462	485	497	506	538	533	556	591	595	1.0 (0.7; 1.4)	2004-2021
	<b>CR</b>	11.3	13.3	13.5	13.2	13.9	13.6	14.8	14.8	14.2	14.3	14.9	15.2	15.4	16.3	16.1	16.7	17.6	17.7		
	<b>ESR2013</b>	11.2	13.1	12.9	12.6	13.0	12.6	13.8	13.5	12.9	13.0	13.4	13.6	13.5	14.1	13.8	14.4	14.8	14.8		
Wallonia	<b>N</b>	222	250	241	267	254	215	269	316	258	296	303	323	279	332	293	302	314	338	1.0 (0.3; 1.8)	2004-2021
	<b>CR</b>	12.8	14.3	13.7	15.1	14.3	12.0	15.0	17.4	14.2	16.2	16.5	17.6	15.1	17.9	15.8	16.3	16.9	18.1		
	<b>ESR2013</b>	12.8	14.2	13.5	14.8	13.8	11.6	14.4	16.6	13.3	15.2	15.5	16.2	14.1	16.7	14.5	14.9	15.2	16.5		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025